Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golden Gate Study of blinatumomab plus low-intensity chemotherapy versus standard chemotherapy in older adults with newly diagnosed Philadelphia-negative B-cell precursor acute lymphoblastic leukemia
NL-OMON53323Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Oct 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute lymphoblastic leukemia (ALL) comparing Blinatumomab alternating with low-intensity chemotherapy with Standard of care chemotherapy (2 arms). Primary endpoints: Event-free survival and Overall survival. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON53323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53323.